当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The emerging role of copper-64 radiopharmaceuticals as cancer theranostics
Drug Discovery Today ( IF 6.5 ) Pub Date : 2018-04-07 , DOI: 10.1016/j.drudis.2018.04.002
Alessandra Boschi , Petra Martini , Emilija Janevik-Ivanovska , Adriano Duatti

Copper radionuclides are rapidly emerging as potential diagnostic and therapeutic tools in oncology, particularly 64Cu-radiopharmaceuticals for targeting neuroendocrine, prostate, and hypoxic tumors. Unexpectedly, experimental results are also revealing the impressive biological behavior of simple [64Cu2+] ions. For example, it has been demonstrated that administration of ionic [64Cu2+] in physiological solution allows the selective targeting of a variety of malignancies. These remarkable biological properties appear to be crucially linked to the natural role of copper ions in cell proliferation. Here, we review the current status of 64Cu-radiopharmaceuticals in molecular imaging and cancer therapy.



中文翻译:

铜64放射性药物作为癌症治疗学的新兴作用

铜放射性核素正迅速成为肿瘤学中潜在的诊断和治疗工具,尤其是针对神经内分泌,前列腺和低氧肿瘤的64种铜放射性药物。出乎意料的是,实验结果还揭示了简单的[ 64 Cu 2+ ]离子令人印象深刻的生物学行为。例如,已证明在生理溶液中施用离子[ 64 Cu 2+ ]可以选择性靶向多种恶性肿瘤。这些非凡的生物学特性似乎与铜离子在细胞增殖中的天然作用至关重要。在这里,我们回顾一下64的当前状态分子成像和癌症治疗中的铜放射性药物。

更新日期:2018-04-07
down
wechat
bug